NCT00251524View on ClinicalTrials.gov

A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Bevacizumab, Oxaliplatin, Pemetrexed

Avastin 15 mg/kg IV, Alimta 500 mg/m2 IV given over 10 minutes, Eloxatin 120 mg/m2 IV given over 2 hours

Trial Locations (1)

43215

Veeda Oncology, Columbus

Sponsors

Collaborators (2)

Sanofi
Genentech, Inc.
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Veeda Oncology

OTHER